Julie Villeneuve

Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes

Ron Goeree, Julie Villeneuve, Jeff Goeree et al. · Journal of Medical Economics · 2016 · 77 citations

Cancer Management, Prognosis, Clinical Endpoint +17

Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics

Natalie Alméras, Jean‐Pierre Després, Julie Villeneuve et al. · The Journal of Clinical Psychiatry · 2004 · 62 citations

August 1999, Cardiometabolic Risk, Psychotropic Medication +16

Longitudinal Comparative Study of Risperidone and Conventional Neuroleptics for Treating Patients With Schizophrenia

Roch-Hugo Bouchard, Chantal Mérette, Emmanuelle Pourcher et al. · Journal of Clinical Psychopharmacology · 2000 · 47 citations

Physician-pharmacist collaborative care in dyslipidemia management: The perception of clinicians and patients

Lyne Lalonde, Éveline Hudon, Johanne Goudreau et al. · Research in Social and Administrative Pharmacy · 2010 · 39 citations

Family Medicine, Physician-pharmacist Collaborative Care, Health Policy +6

An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?

Jason Shafrin, Michelle Skornicki, Michelle Brauer et al. · Health Policy · 2018 · 26 citations